HOUSE_OVERSIGHT_024100.jpg
1.69 MB
Extraction Summary
0
People
37
Organizations
0
Locations
0
Events
1
Relationships
4
Quotes
Document Information
Type:
Financial report / investment schedule
File Size:
1.69 MB
Summary
This document is a confidential financial appendix (Appendix 1) labeled 'Listing of Investments by Fund' for New Leaf Ventures II, L.P., dated March 31, 2014. It details the financial performance of numerous healthcare, therapeutic, and diagnostic companies in the fund's portfolio, split into realized/partially realized and unrealized investments. The document bears a House Oversight Committee stamp and a confidential control number, indicating it is part of a congressional investigation.
Organizations (37)
Relationships (1)
Document lists all companies as investments under New Leaf Ventures II, L.P.
Key Quotes (4)
"Listing of Investments by Fund"Source
HOUSE_OVERSIGHT_024100.jpg
Quote #1
"CONTROL NUMBER 257 - CONFIDENTIAL"Source
HOUSE_OVERSIGHT_024100.jpg
Quote #2
"HOUSE_OVERSIGHT_024100"Source
HOUSE_OVERSIGHT_024100.jpg
Quote #3
"$ amounts in millions, as of March 31, 2014"Source
HOUSE_OVERSIGHT_024100.jpg
Quote #4
Full Extracted Text
Complete text extracted from the document (4,314 characters)
XIII. APPENDICES
Appendix 1
Listing of Investments by Fund
New Leaf Ventures II, L.P.
$ amounts in millions, as of March 31, 2014
Please refer to Endnotes I,J,K,L,M and N in this Appendix.
$ amounts in millions, as of March 31, 2014
Please refer to Endnotes I,J,K,L,M and N in this Appendix.
[Table Headers]
Company | Sector | Vintage Year | Total Cost | Realized Value | Unrealized Value | Total Value | Gross Multiple (Realized Portion) | Gross Multiple (Total) | Gross IRR
Company | Sector | Vintage Year | Total Cost | Realized Value | Unrealized Value | Total Value | Gross Multiple (Realized Portion) | Gross Multiple (Total) | Gross IRR
Realized or Partially Realized Investments
Acadia Pharmaceuticals, Inc. | Therapeutics | 2012 | $ 7.7 | $ 19.4 | $ - | $ 19.4 | 2.51 | 2.51 | 581.9%
Ambit Biosciences, Inc. | Therapeutics | 2013 | $ 10.4 | $ 11.1 | $ - | $ 11.1 | 1.06 | 1.06 | 13.1%
Array Biopharma Inc. | Therapeutics | 2012 | $ 9.0 | $ 20.3 | $ - | $ 20.3 | 2.25 | 2.25 | 74.0%
Audax Health Solutions, Inc. | Convergence | 2011 | $ 3.8 | $ 12.5 | $ 1.6 | $ 14.1 | - | 3.68 | 105.6%
Chimerix, Inc. | Therapeutics | 2011 | $ 20.6 | $ 27.0 | $ 44.9 | $ 71.9 | 3.07 | 3.50 | 57.7%
Epizyme, Inc. | Therapeutics | 2013 | $ 3.4 | $ 6.8 | $ - | $ 6.8 | 2.03 | 2.03 | 1583.0%
Glumetrics, Inc. | Diagnostics & Infrastructure | 2008 | $ 10.7 | $ - | $ - | $ - | - | - | NM
Intercept Pharmaceuticals, Inc. | Therapeutics | 2012 | $ 10.5 | $ 34.1 | $ - | $ 34.1 | 3.24 | 3.24 | 323.6%
Kalidex Pharmaceuticals, Inc. | Therapeutics | 2011 | $ 2.4 | $ 0.2 | $ - | $ 0.2 | 0.07 | 0.07 | -91.6%
MEI Pharma, Inc. | Therapeutics | 2012 | $ 9.0 | $ 10.2 | $ 35.8 | $ 46.0 | 2.94 | 5.12 | 423.2%
Presidio Pharmaceuticals, Inc. | Therapeutics | 2009 | $ 11.0 | $ - | $ - | $ - | - | - | NM
Synageva BioPharma | Therapeutics | 2009 | $ 10.4 | $ 75.7 | $ - | $ 75.7 | 7.30 | 7.30 | 103.3%
Worldheart, Inc. | Healthcare Devices | 2008 | $ 17.0 | $ 1.8 | $ - | $ 1.8 | 0.11 | 0.11 | NM
Acadia Pharmaceuticals, Inc. | Therapeutics | 2012 | $ 7.7 | $ 19.4 | $ - | $ 19.4 | 2.51 | 2.51 | 581.9%
Ambit Biosciences, Inc. | Therapeutics | 2013 | $ 10.4 | $ 11.1 | $ - | $ 11.1 | 1.06 | 1.06 | 13.1%
Array Biopharma Inc. | Therapeutics | 2012 | $ 9.0 | $ 20.3 | $ - | $ 20.3 | 2.25 | 2.25 | 74.0%
Audax Health Solutions, Inc. | Convergence | 2011 | $ 3.8 | $ 12.5 | $ 1.6 | $ 14.1 | - | 3.68 | 105.6%
Chimerix, Inc. | Therapeutics | 2011 | $ 20.6 | $ 27.0 | $ 44.9 | $ 71.9 | 3.07 | 3.50 | 57.7%
Epizyme, Inc. | Therapeutics | 2013 | $ 3.4 | $ 6.8 | $ - | $ 6.8 | 2.03 | 2.03 | 1583.0%
Glumetrics, Inc. | Diagnostics & Infrastructure | 2008 | $ 10.7 | $ - | $ - | $ - | - | - | NM
Intercept Pharmaceuticals, Inc. | Therapeutics | 2012 | $ 10.5 | $ 34.1 | $ - | $ 34.1 | 3.24 | 3.24 | 323.6%
Kalidex Pharmaceuticals, Inc. | Therapeutics | 2011 | $ 2.4 | $ 0.2 | $ - | $ 0.2 | 0.07 | 0.07 | -91.6%
MEI Pharma, Inc. | Therapeutics | 2012 | $ 9.0 | $ 10.2 | $ 35.8 | $ 46.0 | 2.94 | 5.12 | 423.2%
Presidio Pharmaceuticals, Inc. | Therapeutics | 2009 | $ 11.0 | $ - | $ - | $ - | - | - | NM
Synageva BioPharma | Therapeutics | 2009 | $ 10.4 | $ 75.7 | $ - | $ 75.7 | 7.30 | 7.30 | 103.3%
Worldheart, Inc. | Healthcare Devices | 2008 | $ 17.0 | $ 1.8 | $ - | $ 1.8 | 0.11 | 0.11 | NM
Total Realized or Partially Realized Investments | $ 125.9 | $ 219.2 | $ 82.3 | $ 301.5 | 2.01 | 2.39 | 40.6%
[Unrealized Investments Section]
Advanced Cell Diagnostics, Inc. | Diagnostics & Infrastructure | 2012 | $ 9.0 | $ - | $ 9.0 | $ 9.0 | - | 1.00 | -0.4%
Afferent Pharmaceuticals, Inc. | Therapeutics | 2009 | $ 11.2 | $ - | $ 11.2 | $ 11.2 | - | 1.00 | 0.0%
Altura Medical, Inc. | Healthcare Devices | 2010 | $ 10.7 | $ - | $ 8.3 | $ 8.3 | - | 0.77 | -12.3%
AwarePoint Corporation | Convergence | 2011 | $ 12.8 | $ - | $ 14.1 | $ 14.1 | - | 1.10 | 5.7%
Calchan Holdings LTD | Therapeutics | 2011 | $ 5.2 | $ - | $ - | $ - | - | - | NM
CardioKinetix, Inc. | Healthcare Devices | 2011 | $ 12.0 | $ - | $ 12.0 | $ 12.0 | - | 1.00 | 0.0%
Convergence Pharmaceuticals, Ltd | Therapeutics | 2010 | $ 7.4 | $ - | $ 7.6 | $ 7.6 | - | 1.03 | 1.0%
Durata Therapeutics, Inc. | Therapeutics | 2009 | $ 25.0 | $ - | $ 40.8 | $ 40.8 | - | 1.63 | 21.2%
iRhythm Technologies, Inc. | Convergence | 2011 | $ 11.1 | $ - | $ 11.6 | $ 11.6 | - | 1.04 | 1.6%
Karos Pharmaceuticals, Inc. | Therapeutics | 2010 | $ 7.6 | $ 0.1 | $ 7.5 | $ 7.6 | - | 1.00 | 0.0%
Karus Therapeutics Ltd | Therapeutics | 2012 | $ 5.8 | $ - | $ 5.8 | $ 5.8 | - | 1.00 | 0.0%
Karyopharm Therapeutics, Inc. | Therapeutics | 2013 | $ 1.0 | $ - | $ 4.2 | $ 4.2 | - | 4.17 | 1638.7%
Kitcheck, Inc. | Convergence | 2013 | $ 3.7 | $ - | $ 3.7 | $ 3.7 | - | 1.00 | 0.0%
Neuronetics, Inc. | Healthcare Devices | 2009 | $ 20.3 | $ - | $ 21.9 | $ 21.9 | - | 1.08 | 2.0%
NY Digital Health, LLC | Convergence | 2012 | $ 0.4 | $ - | $ 0.4 | $ 0.4 | - | 1.00 | 0.1%
Oxford Immunotec | Diagnostics & Infrastructure | 2009 | $ 11.3 | $ - | $ 27.1 | $ 27.1 | - | 2.41 | 28.3%
Principia BioPharma, Inc. | Therapeutics | 2011 | $ 9.7 | $ - | $ 9.7 | $ 9.7 | - | 1.00 | 0.0%
Spiracur, Inc | Healthcare Devices | 2009 | $ 12.0 | $ - | $ 8.5 | $ 8.5 | - | 0.70 | -8.4%
TigerText, Inc. | Convergence | 2012 | $ 4.6 | $ 0.0 | $ 5.6 | $ 5.7 | - | 1.25 | 22.6%
Treato Pharma | Convergence | 2013 | $ 3.0 | $ - | $ 3.0 | $ 3.0 | - | 1.00 | 0.0%
Truveris, Inc. | Convergence | 2012 | $ 6.5 | $ - | $ 6.5 | $ 6.5 | - | 1.00 | 0.0%
Versartis, Inc. | Therapeutics | 2011 | $ 21.2 | $ - | $ 93.6 | $ 93.6 | - | 4.41 | 129.4%
Public Investments | Therapeutics | 2011 | $ 20.6 | $ 13.1 | $ 29.5 | $ 42.6 | - | 2.07 | 42.5%
Advanced Cell Diagnostics, Inc. | Diagnostics & Infrastructure | 2012 | $ 9.0 | $ - | $ 9.0 | $ 9.0 | - | 1.00 | -0.4%
Afferent Pharmaceuticals, Inc. | Therapeutics | 2009 | $ 11.2 | $ - | $ 11.2 | $ 11.2 | - | 1.00 | 0.0%
Altura Medical, Inc. | Healthcare Devices | 2010 | $ 10.7 | $ - | $ 8.3 | $ 8.3 | - | 0.77 | -12.3%
AwarePoint Corporation | Convergence | 2011 | $ 12.8 | $ - | $ 14.1 | $ 14.1 | - | 1.10 | 5.7%
Calchan Holdings LTD | Therapeutics | 2011 | $ 5.2 | $ - | $ - | $ - | - | - | NM
CardioKinetix, Inc. | Healthcare Devices | 2011 | $ 12.0 | $ - | $ 12.0 | $ 12.0 | - | 1.00 | 0.0%
Convergence Pharmaceuticals, Ltd | Therapeutics | 2010 | $ 7.4 | $ - | $ 7.6 | $ 7.6 | - | 1.03 | 1.0%
Durata Therapeutics, Inc. | Therapeutics | 2009 | $ 25.0 | $ - | $ 40.8 | $ 40.8 | - | 1.63 | 21.2%
iRhythm Technologies, Inc. | Convergence | 2011 | $ 11.1 | $ - | $ 11.6 | $ 11.6 | - | 1.04 | 1.6%
Karos Pharmaceuticals, Inc. | Therapeutics | 2010 | $ 7.6 | $ 0.1 | $ 7.5 | $ 7.6 | - | 1.00 | 0.0%
Karus Therapeutics Ltd | Therapeutics | 2012 | $ 5.8 | $ - | $ 5.8 | $ 5.8 | - | 1.00 | 0.0%
Karyopharm Therapeutics, Inc. | Therapeutics | 2013 | $ 1.0 | $ - | $ 4.2 | $ 4.2 | - | 4.17 | 1638.7%
Kitcheck, Inc. | Convergence | 2013 | $ 3.7 | $ - | $ 3.7 | $ 3.7 | - | 1.00 | 0.0%
Neuronetics, Inc. | Healthcare Devices | 2009 | $ 20.3 | $ - | $ 21.9 | $ 21.9 | - | 1.08 | 2.0%
NY Digital Health, LLC | Convergence | 2012 | $ 0.4 | $ - | $ 0.4 | $ 0.4 | - | 1.00 | 0.1%
Oxford Immunotec | Diagnostics & Infrastructure | 2009 | $ 11.3 | $ - | $ 27.1 | $ 27.1 | - | 2.41 | 28.3%
Principia BioPharma, Inc. | Therapeutics | 2011 | $ 9.7 | $ - | $ 9.7 | $ 9.7 | - | 1.00 | 0.0%
Spiracur, Inc | Healthcare Devices | 2009 | $ 12.0 | $ - | $ 8.5 | $ 8.5 | - | 0.70 | -8.4%
TigerText, Inc. | Convergence | 2012 | $ 4.6 | $ 0.0 | $ 5.6 | $ 5.7 | - | 1.25 | 22.6%
Treato Pharma | Convergence | 2013 | $ 3.0 | $ - | $ 3.0 | $ 3.0 | - | 1.00 | 0.0%
Truveris, Inc. | Convergence | 2012 | $ 6.5 | $ - | $ 6.5 | $ 6.5 | - | 1.00 | 0.0%
Versartis, Inc. | Therapeutics | 2011 | $ 21.2 | $ - | $ 93.6 | $ 93.6 | - | 4.41 | 129.4%
Public Investments | Therapeutics | 2011 | $ 20.6 | $ 13.1 | $ 29.5 | $ 42.6 | - | 2.07 | 42.5%
Total Unrealized Investments | $ 232.1 | $ 13.2 | $ 341.4 | $ 354.6 | - | 1.53 | 20.4%
Total New Leaf Ventures II, L.P. Investments | $ 358.0 | $ 232.4 | $ 423.7 | $ 656.1 | 2.01 | 1.83 | 29.6%
89
CONTROL NUMBER 257 - CONFIDENTIAL
HOUSE_OVERSIGHT_024100
CONTROL NUMBER 257 - CONFIDENTIAL
HOUSE_OVERSIGHT_024100
Discussion 0
No comments yet
Be the first to share your thoughts on this epstein document